Is the natural product screening activity declining?
Abstracts of Asian Mycological Congress 2000, Hong Kong SAR, China. 9-13 July 2000. 32p.
The expectation toward fungal metabolites was tremendous since blockbuster drugs such as mevalotina and cyclosporine were launched more than a decade ago. During these years, meanwhile, technologies for drug discovery process have been highly advanced and diversified. Pharmaceutical industries are keeping up with heavy competition with high-throughput screening (HTS), combinatorial chemistry and genomics. The better-faster-cheaper strategy tends to dive out the natural products screening (NPS) programs, which take time and cost much. Recently, we took a survey of the NPS activities by sending questionnaires to various organizations mainly in Japan. 73% of them are conducting NPS. However, they are facing difficulties including pure technological problems to cope with HTS and more political issues such as Conventions on Biological Diversity. I will discuss trends and future in the NPS programs form a viewpoint of mycology. I will also touch on discussions on collaboration between Asian countries and Japanfs biological resource center.Go back to the list of publication
To the relevant abstract in Japanese
Reprint request to Toru Okuda
Last update on
Copyright © TorulopsisOktavianus